Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of resistance mutations to nevirapine as part of triple-drug therapy in children.

Pharmacotherapy - 1 Jan 2002

Seifert Lynn L

Abstract excerpt

Five children received nevirapine, a nonnucleoside reverse transcriptase inhibitor used as part of a triple-drug regimen to treat human immunodeficiency virus infection. They all developed resistance mutations to the agent within 4-10 months. They differed in compliance with drug therapy and development of specific mutations. Whether these mutations predict clinical resistance has yet to be determined.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiretroviral Therapy, Highly Active
Share to Child, Preschool
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Reverse Transcriptase

Share to Nevirapine

Share to Reverse Transcriptase Inhibitors

Source

Identifiers

PMID: 11794422
DOI: 10.1592/phco.22.1.113.33494

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of resistance mutations to nevirapine as part of triple-drug therapy in children.PMID 11794422Read ↗

HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors.Semantic proximity Read ↗

Low-frequency nevirapine resistance at multiple sites may predict treatment failure in infants on nevirapine-based treatment.Semantic proximity Read ↗

Nevirapine resistance in human immunodeficiency virus type 1-positive infants determined using dried blood spots stored for up to six years at room temperature.Semantic proximity Read ↗

Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.Semantic proximity Read ↗

Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316.Semantic proximity Read ↗

Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India.Semantic proximity Read ↗

HIV-1 drug resistance and mother-to-child transmission.Semantic proximity Read ↗

Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.Semantic proximity Read ↗

Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children.Semantic proximity Read ↗

Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.Semantic proximity Read ↗

NevirapineSemantic proximity Read ↗

Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.